stutes
11 Jul 2019
Stroke update 40 clinical sites to set up, 104 patients to recruit and yet Rene seem to be hitting US regulatory bureaucracy in getting site approvals? Why do you need 40 sites; why not fewer,with patients being transported to clinics? Makes you wonder about US bureaucracy.
loper
10 Jul 2019
Stroke update Stroke update will be very welcome. RENE appear to be the only company doing work on mature stroke. The potential market is vast. The last announcement re the progress of the human retinal cell trial was on 26/4/2019 ie two and a half months ago. It was very encouraging indeed. The next progress report must be in a month or so , at which time the first patient group of the 2a trial will be at 90 and 150 days post treatment. If the rate of improvement in eyesight is maintained then the impact on the share price could be significant.
stutes
02 Jul 2019
Stroke update medicalxpress.com First US patient in novel stem cell trial for stroke disability enrolled at... The first U.S. patient to participate in a global study of a stem cell therapy injected directly into the brain to treat stroke disability was enrolled in the clinical trial this week at The University of Texas Health Science Center at Houston... Looking forward to stroke update, will Rene opt to setup another trial in China to speed up trial and data?
stutes
01 Jul 2019
Rene faces same pressure as Woodford Rene needs to deliver on its promises or face the same pressure as Woodford funds, ie, shareholders forcing changes.
charlton_vach
25 Jun 2019
Woodford Until he has sold the share price will be suppressed. He’s shifting shedloads so it could be a while.
stutes
20 Jun 2019
Woodford It seems Woodford is selling; will the new shareholders be more demanding than patient?
stutes
20 Jun 2019
Share price You have to wonder if recent price movements are fair based on volume or news update?
stutes
12 Jun 2019
Share price Down 12.5p on 41k volume. Makes you wonder…
stutes
07 Jun 2019
Woodford funds If Woodford’s holding in Rene falls I see it as an opportunity for other fund managers to come on board on put pressure on Rene to deliver.
Armageddon
07 Jun 2019
Woodford funds I’m short reneuron . Big day today 're May 250 test. Hard to know until near close if it will relent or not . Decide then
Rhino1958
07 Jun 2019
Woodford funds I agree No negative news for the company (Reneuron) and it remains a stock that could excel if the current trials continue to show further improvement
stutes
07 Jun 2019
Woodford funds The reported problems at some of Woodford funds may be affecting Rene’s share price - namely the redemptions and loss of key mandates?
stutes
09 May 2019
Stroke data now set for H2 2020 Time for a new Board that hits dates and targets.
s.golzari
01 May 2019
Share price volatility Precisely because it is a Plc. It’s also to be expected in rene’s case given the rapid rise which would have attracted “traders†and then hit the ceiling of 335 at which those bandwagon riders cash in and move on. In recent weeks, when the price ceilinged at 230 it retreated to 200 and when it hit 260 it went to 225. Nothing unusual.
stutes
01 May 2019
Share price volatility How can a plc lose 10% on 320k volume, on a no news day, yet analysts that follow the business all say it is under valued?
